BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2019 4:43:36 AM | Browse: 1235 | Download: 3105
 |
Received |
|
2019-06-17 00:25 |
|
Peer-Review Started |
|
2019-06-17 05:55 |
|
First Decision by Editorial Office Director |
|
2019-07-21 01:22 |
|
Return for Revision |
|
2019-07-24 00:51 |
|
Revised |
|
2019-07-30 06:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-08-16 09:24 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-08-19 13:32 |
|
Articles in Press |
|
2019-08-19 13:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-09-04 03:22 |
|
Publish the Manuscript Online |
|
2019-09-07 04:43 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Won Hyeok Choe, Ki Jeong Kim, So Young Lee, Yu Min Choi, So Young Kwon, Jeong Han Kim and Bum Joon Kim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bum Joon Kim, PhD, Professor, Department of Biomedical Sciences, Microbiology and Immunology, Liver Research Institute, Cancer Research Institute and SNUMRC, College of Medicine, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. kbumjoon@snu.ac.kr |
| Key Words |
Chronic hepatitis B; Entecavir; Hepatitis B virus; Liver fibrosis; Mutation; Tenofovir |
| Core Tip |
Hepatitis B virus (HBV) DNA polymerase mutations have been known to be prevalent in treatment-naïve chronic hepatitis B (CHB) patients infected with HBV genotype C2 strains. The newly developed locked nucleotide probe based real-time PCR method could discriminate the naturally-occurring rtM204I mutations from wild type with high sensitivity in treatment-naïve patients. Multivariate analyses showed that the naturally-occurring rtM204I variants were more frequently pre-existed in patients with liver fibrosis, and the pre-existence of the naturally-occurring rtM204I variants were significantly associated with incomplete viral response to nucleos(t)ide analogues. Tenofovir is a more suitable nucleos(t)ide analogues than entecavir for treatment-naïve CHB patients carrying the naturally occurring rtM204I mutations. |
| Publish Date |
2019-09-07 04:43 |
| Citation |
Choe WH, Kim KJ, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019;25(33): 4985-4998 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i33/4985.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i33.4985 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
